Results 231 to 240 of about 731,609 (299)

The burden of COVID‐19 in hospitalized people with diabetes mellitus in Brazil: Insights from four years of the pandemic

open access: yesDiabetic Medicine, EarlyView.
Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo   +4 more
wiley   +1 more source

Indoleamine 2,3‐Dioxygenase 1 as an Adjunctive Histopathological Marker of Cholangitis Activity in Primary Biliary Cholangitis

open access: yesHepatology Research, EarlyView.
IDO‐1 immunostaining identifies primary biliary cholangitis even in morphologically subtle bile duct lesions. IDO‐1 expression reflects cholangitis activity and is suppressed by ursodeoxycholic acid treatment, indicating its value as a dynamic diagnostic adjunct rather than a static marker of chronic damage.
Kaori Yoshimura   +10 more
wiley   +1 more source

Would patients over 65 years of age accept vaccination while hospitalised? An assessment of eligibility and acceptability

open access: yesInternal Medicine Journal, EarlyView.
Abstract Background Vaccination is effective at preventing severe illness related to influenza, pneumococcal disease and coronavirus disease 2019 COVID‐19. Vaccine coverage among older Australians is incomplete, and hospitals currently administer very few vaccine doses.
Victoria Deacon   +5 more
wiley   +1 more source

An Upsurge of Measles Cases in Mali-a Consequence of Pandemic-associated Disruption in Routine Immunization. [PDF]

open access: yesOpen Forum Infect Dis
Nampota-Nkomba N   +13 more
europepmc   +1 more source

Australian consensus recommendations for the management of increased meningococcal infection risk in adults with neurological diseases treated with complement inhibitors

open access: yesInternal Medicine Journal, EarlyView.
Abstract Complement inhibitor therapy carries a risk of serious infections, including meningococcal disease. Here we provide evidence‐based recommendations and expert consensus for immunisation and prophylactic treatment of patients receiving, or planning to receive, complement inhibitors for neurological conditions in the Australian setting.
Katherine A. Buzzard   +13 more
wiley   +1 more source

Preventing infections after CD19‐directed chimeric antigen receptor T‐cell therapies for lymphoma: a consensus practice statement

open access: yesInternal Medicine Journal, EarlyView.
Abstract Chimeric antigen receptor (CAR) T‐cell therapies directed against cluster of differentiation 19 (CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt.
Aine Hurley   +15 more
wiley   +1 more source

Correlates of Uptake of Routine Immunization amongst Under-Five Children: Comparison of Nomadic and Non-nomadic Fulani in Yobe State, Nigeria. [PDF]

open access: yesNiger Med J
Abdulhamid D   +13 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy